About Us

Our Vision & Mission

L2P Research is founded with a vision to provide integrated R&D support in all the key areas of Pre-clinical Research.

Our Story

L2P Research was founded in 2015 by Dr. Anaganti. After 2 years of struggle and hard work, L2P Labs is now one of the fast growing Research organization in New york. Dr. Anaganti has Over 15 years of experience in various areas of Pharmaceutical industry, Specialized in Preclinical development, GxPs compliance, Auditing and quality management. As a researcher at National cancer institute (NIH) and International agency for research in cancer (IARC- WHO), Dr. Anaganti envisioned establishing a research organization that conducts research with precision and integrity. Dr. Anaganti serves as technical reviewer for ‘Quality progress’ a prestigious journal published by American Society for Quality.

We provide a complete array of research services as required for Investigational New Drug Applications (IND). L2P Research Labs at Stony Brook New York is fully committed to the judicious, humane use of animals in research and development. We operate in AAALAC accredited and GLP compliant audited facilities.

We offer proprietary orthotopic and metastases tumor models. Our services include Efficacy studies, Immuno-oncology models, IND enabling GLP/Non-GLP studies, Whole Body Animal Imaging, small animal ultra sound MRI, PDX tumor models, CT scan and other advanced technologies.

L2P Research Milestone

  • 2015
    • Started Our Journey
  • 2016
    • Successfully established wide portfolio of syngeneic tumor models, Achieved capabilities to perform IND enabling studies
  • 2017
    • Successfully filed our first IND
  • 2018
    • Data from our studies was featured in prestigious journal Cell, L2P Research is now registered Trademark with USTPO
  • 2019
    • Acquired Metis Laboratories Inc., Completed 6 IND filings, Extensively offered animal research services to companies with Small business and NIH grants
  • 2020
    • Established spontaneous models for Pancreatic, Breast and Lung cancers, Added GLP-Bioanalytical services to our portfolio
  • Sustained Growth

Note From CEO

Having worked several years in a pre-clinical CROs, I understand that each Investigational new drug is unique, thus we at L2P Research work with each customer individually to provide services with high professional capabilities, responsiveness and integrity. As per our internal policy, study directors at L2P will not handle more than one project at a time. This is to ensure that the project is handled with highest priority for best quality and timely delivery of results.

As a member of minority owned small business coalition, committed to stimulate local economy and provide employment opportunities within the community, our business model is to provide services at affordable costs and eventually build long-term relationships with our customers.

Our work ethics adhere to strict quality control methods and meet the highest industrial standards.

Our Research Facilities